All Posts Tagged With: "MYGN"
(QGEN) Qiagen Expands with New Deals
In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement,...
13Jan2012 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics Analyst Uprades Shares to Outperform
Recently, we upgraded Myriad Genetics (MYGN) to Outperform with a target price of $27.00. Myriad is confident of retaining the momentum recorded over the past few quarters going ahead through product portfolio expansion, targeting the companion diagnostic market and expansion...
1Jul2011 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics – Bull of the Day
Myriad Genetics’ (MYGN) flagship product, Bracanalysis, has been recording robust growth over the past few quarters. Moreover, the company is undertaking strategies to expand the scope of the test. A strong cash balance enables the company to buyback shares, expand into...
1Jul2011 | vitalstocks | 0 comments | Continued(ANGO) Company News for June 16, 2011 – Corporate Summary
• Share prices of Scotts Miracle-Gro Company (NYSE:SMG) dipped 6.02% after the company reduced its earnings estimate for the fiscal year 2011 • Shares of Owens-Illinois (NYSE:OI) dropped 13.54% to close at $25.54 after the company said its second quarter earnings...
16Jun2011 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing
Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter’s phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for treatment of...
9Apr2011 | vitalstocks | 0 comments | Continued(HUM) June 2010 – Industry Outlook – Health Care Stock Review
The health care sector comprises different industries, ranging from managed care organizations, healthcare facilities providers and medical devices manufacturers to biotech and pharmaceutical companies. Consequently, we believe that investors in this sector should be mindful...
3Jun2010 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics – Bear of the Day
Myriad Genetics Inc.’s (MYGN) third quarter fiscal 2010 earnings of $0.33 per share fell short of the Zacks Consensus Estimate by $0.05. The company had earned $0.38 per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July 2009 to focus...
23May2010 | vitalstocks | 0 comments | Continued(MYGN) Myriad Surpasses Consensus Estimates
Myriad Genetics Inc. (MYGN) reported second quarter fiscal 2010 earnings of 36 cents per share, two cents above the Zacks Consensus Estimate. The company had earned 22 cents in the year-ago period. The year-ago earnings were inclusive of a loss of $15.6 million from discontinued...
4Feb2010 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics Upgraded to Neutral
We have upgraded Myriad Genetics (MYGN) to Neutral from Underperform based on the impressive performance of its molecular diagnostics business. Effective July 1, 2009, the company spun off its therapeutics business to focus on molecular diagnostics. We believe that the de-risking...
17Dec2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics – Bear of the Day
Myriad Genetics Inc. (MYGN) reported first quarter fiscal 2010 earnings of 31 cents per share, which was below the Zacks Consensus Estimate by a penny. The company had earned 25 cents per share in the year-ago period. Myriad Genetics spun off its therapeutics business in July...
16Nov2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics Inc Misses Forecasts by a Penny
Myriad Genetics Inc. (MYGN) reported fiscal first-quarter earnings of 31 cents per share, a penny behind the Zacks Consensus Estimate. The company had earned 25 cents in the year-ago period. Molecular diagnostic revenues for the quarter came in at $85.12 million as against $69.97...
8Nov2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Reports Strong Earnings of 37 Cents vs. 23 Cents Estimate
Yesterday, Myriad Genetics Inc. (MYGN) reported fourth quarter earnings of 37 cents per share from continuing operations. This was well above the Zacks Consensus Estimate of 23 cents. For fiscal year 2009, the company earned $1.38 per share from continuing operations. Molecular...
26Aug2009 | vitalstocks | 0 comments | Continued(MYGN) Biotech Industry – Zacks Analyst Interviews
OVERVIEW The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over...
1Jun2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics, Inc. – Momentum – Zacks Rank Buy
Myriad Genetics, Inc. (MYGN) continues to head higher after the company reported strong earnings on Feb 3 and announced a 2-for-1 stock split on Feb 24. Second-Quarter Results Much of Myriad’s recent price strength is built upon the company’s solid second-quarter...
16Mar2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics – Revenues increased 58%, on a year-over-year basis
Myriad Genetics, Inc. (MYGN) has just reported a fantastic quarter and shares have responded. Analysts are responding with sharp increases in earnings estimates. Company Description Myriad Genetics uses gene-based medicine to develop therapeutic and molecular diagnostic products....
10Feb2009 | vitalstocks | 0 comments | Continued(MYGN) Myriad Genetics – Revenue increased 53% from last year
Myriad Genetics, Inc.’s (MYGN) share price continues to advance after the company reported a great quarter in early November. Analysts are bullish on the company, with the next-year estimate projecting 60% earnings growth. Company Description Myriad Genetics is a healthcare...
14Jan2009 | Shawn | 0 comments | Continued